Mounjaro vs. Ozempic: What's the Difference?

If you've been researching weight loss medications, you've almost certainly come across both Mounjaro and Ozempic. Both are injectable, both are taken once weekly, and both belong to a class of drugs called GLP-1 receptor agonists. But they're not the same medication — and understanding the differences can help you have a much more productive conversation with your prescriber.

The Basics: What Are These Medications?

Ozempic (Semaglutide)

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It was originally approved by the FDA in 2017 for type 2 diabetes management. In 2021, the same molecule at a higher dose was approved under the brand name Wegovy specifically for chronic weight management. When people say "Ozempic for weight loss," they're often referring to the off-label use of the diabetes dose, though Wegovy is the FDA-approved weight loss version.

Mounjaro (Tirzepatide)

Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. It was approved by the FDA in 2022 for type 2 diabetes. In 2023, the same molecule was approved under the brand name Zepbound for chronic weight management. Tirzepatide is technically a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

The Key Difference: Single vs. Dual Receptor Action

This is the most important distinction between the two medications.

Semaglutide (Ozempic/Wegovy) works by mimicking the GLP-1 hormone — it slows gastric emptying, suppresses appetite signals in the brain, and improves insulin sensitivity. One receptor, one mechanism.

Tirzepatide (Mounjaro/Zepbound) mimics both GLP-1 and GIP. GIP is another gut hormone that, when activated alongside GLP-1, appears to amplify fat breakdown and further reduce appetite. The combination of two receptor pathways is believed to be the reason tirzepatide produces greater average weight loss than semaglutide in clinical trials.

Weight Loss Results: What the Trials Show

Let's look at the landmark clinical trial data side by side:

Semaglutide (STEP 1 Trial)

• Average weight loss: ~15% of total body weight over 68 weeks
• Participants losing ≥5%: 86%
• Participants losing ≥10%: 69%
• Participants losing ≥15%: 50%

Tirzepatide (SURMOUNT-1 Trial)

• Average weight loss at 10 mg dose: ~19.5% of total body weight over 72 weeks
• Average weight loss at 15 mg dose: ~20.9% of total body weight
• Participants losing ≥20%: 57% at the highest dose
• Participants losing ≥25%: 36% at the highest dose

The difference is meaningful: tirzepatide produces roughly 5–6 percentage points more weight loss on average, and a significantly higher proportion of patients achieve 20%+ weight loss. For a 250-pound person, that's the difference between losing ~37 lbs vs. ~52 lbs on average.

Side Effects: How Do They Compare?

Both medications share a similar side effect profile because they both activate GLP-1 receptors. The most common issues are:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea or constipation
• Reduced appetite (intended effect, but can feel uncomfortable)
• Fatigue during early weeks

In clinical trials, GI side effects were slightly more common with tirzepatide at higher doses, though most patients found them manageable. Both medications use a slow, multi-month dose escalation protocol specifically to minimize GI discomfort.

Rare but serious risks are similar for both: pancreatitis, gallbladder disease, and — based on animal studies — a theoretical concern about thyroid c-cell tumors. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Dosing and Administration

Both medications are self-administered as a subcutaneous injection (just under the skin) once weekly. Most patients choose the abdomen, thigh, or upper arm. The injection process is quick and straightforward — comparable to an insulin pen.

Semaglutide (Wegovy) Dosing Schedule

• 0.25 mg weekly × 4 weeks
• 0.5 mg weekly × 4 weeks
• 1.0 mg weekly × 4 weeks
• 1.7 mg weekly × 4 weeks
• 2.4 mg weekly (maintenance dose)

Tirzepatide (Zepbound/Mounjaro) Dosing Schedule

• 2.5 mg weekly × 4 weeks
• 5.0 mg weekly × 4 weeks
• Then increase by 2.5 mg increments every 4 weeks as tolerated
• Maximum dose: 15 mg weekly

Cost and Insurance Coverage

Both medications carry significant list prices without insurance:

• Wegovy (semaglutide 2.4 mg): ~$1,300/month list price
• Zepbound (tirzepatide): ~$1,060/month list price
• Ozempic (semaglutide for diabetes): ~$900–$1,000/month list price
• Mounjaro (tirzepatide for diabetes): ~$1,000/month list price

Insurance coverage varies widely. Many plans cover Ozempic/Mounjaro for diabetes but are more restrictive about the weight loss versions. Manufacturer savings cards can bring costs down significantly for commercially insured patients.

Compounded alternatives: Through licensed telehealth providers, compounded semaglutide and tirzepatide are available at $150–$400/month — a fraction of brand-name pricing. These are prepared by licensed compounding pharmacies and prescribed by licensed physicians. Learn more about Truventa's weight loss program and how we approach GLP-1 prescribing for our patients.

Which One Should You Choose?

Here's a practical framework:

• Choose tirzepatide (Mounjaro/Zepbound) if: You want the highest probability of maximum weight loss, your physician agrees you're a good candidate, and you can tolerate the dose escalation.
• Choose semaglutide (Ozempic/Wegovy) if: You've had good results on it previously, you have insurance that covers it but not tirzepatide, or your physician recommends it for your specific health profile.
• Both are excellent choices compared to placebo and non-medication approaches. Either drug is far more effective than diet and exercise alone for most people with obesity.

For a deeper look at how these medications compare to surgical options, see our article on weight loss surgery vs. GLP-1 medications. Or if you're curious about how semaglutide works at a biological level, visit our semaglutide explainer.

The Bottom Line

Mounjaro/Zepbound (tirzepatide) and Ozempic/Wegovy (semaglutide) are both highly effective weekly injectable weight loss medications. Tirzepatide's dual GIP+GLP-1 mechanism produces higher average weight loss in clinical trials — roughly 20% vs. 15% of total body weight. Side effects are similar for both. Cost without insurance is comparable, though compounded versions of both are available through telehealth providers at significantly lower prices.

The best medication is the one your licensed provider determines is right for your specific health history, goals, and situation. A telehealth evaluation is the fastest way to find out which option makes sense for you.